


Gross et al., "Antitumor Activity of the Glutaminase Inhibitor CB-839 in TNBC"
Supplementary Figure S3



Supplementary Figure S3. TNBC primary tumors and cell lines have elevated glutaminase (GAC) mRNA levels. A, expression levels for *GAC*, *KGA*, *GLUL* and *GLS2* in normal breast tissue, TNBC tumors, and receptor-positive tumors from the TCGA breast invasive carcinoma dataset. The log₂ transformed expression levels for each gene are plotted; "whiskers" span the 5th to 95th percentile with data outside this range shown as individual data points. B, expression levels for *GAC*, *KGA*, *GLUL* and *GLS2* in TNBC and receptor-positive breast cancer cell lines from the CCLE dataset. log₂ transformed expression values are plotted as in (A). Statistical comparisons were performed by one-way ANOVA (A) or unpaired t-test (B): * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.